mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
PRL-3 Inhibitor I |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.03 |
0.4 |
mRNA |
NVP-BSK805 |
CTRPv2 |
pan-cancer |
AAC |
0.027 |
0.4 |
mRNA |
BRD-K09344309 |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.4 |
mRNA |
A-770041 |
GDSC1000 |
pan-cancer |
AAC |
-0.04 |
0.4 |
mRNA |
Y-39983 |
GDSC1000 |
pan-cancer |
AAC |
0.025 |
0.4 |
mRNA |
ZSTK474 |
GDSC1000 |
pan-cancer |
AAC |
0.024 |
0.4 |
mRNA |
GDC-0879 |
CTRPv2 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
isoevodiamine |
CTRPv2 |
pan-cancer |
AAC |
-0.025 |
0.4 |